Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Jan 25, 2011

Premium

Innopsys has appointed Reuben Dharmaraj as US sales director for its high-resolution microarray scanners product line. Dharmaraj joins Carbonne, France-based Innopsys from life science consulting firm Ab Initio Pharmacodynamics. He has also held sales, marketing, and support positions at PerkinElmer, Aurora Biosciences, and Unisyn Technologies. He is also a founding principal at ChloroFill, a green structural material firm.

Dharmaraj holds an MSc in molecular glycobiology from the University of Tulsa and a BSc in the biosciences from Oral Roberts University. He will be based out of Innopsys' new US office in Chicago (BAN 11/4/2010).


Roche's Erich Hunziker plans to retire as chief financial officer, chief information officer, and deputy head of the corporate executive committee at the end of March. The firm's board of directors has appointed Alan Hippe to take over Hunziker's position as CFO. He will also be on Roche's corporate executive committee. He had been CFO at ThysenKrupp.


WaferGen Biosystems has appointed Arul Chinnaiyan to serve on its scientific advisory board. Chinnaiyan is currently director of the Michigan Center for Translational Pathology, and an investigator at the Howard Hughes Medical Institute.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.